Mar 2, 2009 | Laboratory News, Laboratory Pathology
Acquisition will particularly strengthen Beckman’s presence in clinical chemistry market Monday, March 2, 2009 Last Friday, Beckman Coulter Inc. (NYSE:BEC) announced that it will pay $800 million acquire the diagnostics business of Olympus Corporation. This is a major transaction that further consolidates the in vitro diagnostics (IVD) industry, particularly given the respective market shares in clinical chemistry currently held by both Beckman and Olympus. A Japanese firm headquartered...
